PRQR
Closed
Proqr Therapeutics Bv
2.01
-0.03 (-1.47%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 2.04
Day's Range: 2. - 2.085
Send
sign up or login to leave a comment!
When Written:
2.1805
ProQR Therapeutics BV is a biotechnology company that focuses on developing RNA-based therapies for rare genetic diseases. The company was founded in 2012 and is headquartered in Leiden, the Netherlands, with additional offices in the United States.
ProQR Therapeutics BV's pipeline includes potential treatments for cystic fibrosis, Leber congenital amaurosis (LCA), Usher syndrome, and other genetic disorders. The company's lead drug candidate, QR-110, is being developed for the treatment of LCA 10, a rare genetic disease that causes blindness in children.
ProQR Therapeutics BV uses proprietary RNA repair technology to develop therapies that target the underlying cause of genetic diseases. The company's approach involves using small pieces of RNA to correct genetic mutations and restore normal protein function.
ProQR Therapeutics BV is a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol "PRQR." The company has partnerships with various research institutions and organizations, including the Cystic Fibrosis Foundation and the Foundation Fighting Blindness.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
ProQR Therapeutics BV's pipeline includes potential treatments for cystic fibrosis, Leber congenital amaurosis (LCA), Usher syndrome, and other genetic disorders. The company's lead drug candidate, QR-110, is being developed for the treatment of LCA 10, a rare genetic disease that causes blindness in children.
ProQR Therapeutics BV uses proprietary RNA repair technology to develop therapies that target the underlying cause of genetic diseases. The company's approach involves using small pieces of RNA to correct genetic mutations and restore normal protein function.
ProQR Therapeutics BV is a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol "PRQR." The company has partnerships with various research institutions and organizations, including the Cystic Fibrosis Foundation and the Foundation Fighting Blindness.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!